1. Home
  2. LASR vs GLPG Comparison

LASR vs GLPG Comparison

Compare LASR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$48.01

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$34.39

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
GLPG
Founded
2000
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
LASR
GLPG
Price
$48.01
$34.39
Analyst Decision
Strong Buy
Hold
Analyst Count
7
4
Target Price
$36.29
$31.33
AVG Volume (30 Days)
683.4K
122.2K
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,526,000.00
$336,643,201.00
Revenue This Year
$31.18
$1.76
Revenue Next Year
$11.31
$0.49
P/E Ratio
N/A
N/A
Revenue Growth
12.05
10.31
52 Week Low
$6.20
$22.36
52 Week High
$47.50
$37.78

Technical Indicators

Market Signals
Indicator
LASR
GLPG
Relative Strength Index (RSI) 80.69 67.07
Support Level $42.94 $32.13
Resistance Level $47.50 $34.48
Average True Range (ATR) 2.59 0.82
MACD 0.62 0.06
Stochastic Oscillator 96.60 92.61

Price Performance

Historical Comparison
LASR
GLPG

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: